Literature DB >> 16598418

Phosphorylation of cAMP response element binding protein (CREB) as a marker of hypoxia in pituitary adenoma.

Daijiro Morimoto1, Daizo Yoshida, Masahiro Noha, Masanori Suzuki, R Yoshiyuki Osamura, Akira Teramoto.   

Abstract

Hypoxia appears to be causatively related to pituitary adenoma. Currently, no biomarkers are available for the postoperative assessment of hypoxia in patient samples. Since the cAMP response element binding protein (CREB) is phosphorylated under hypoxic conditions, we examined whether CREB phosphorylation levels may be exploited as a novel biomarker for hypoxia in pituitary adenoma tissues. HP-75 human pituitary adenoma cells were incubated in 21% or 1% oxygen (normoxia and hypoxia, respectively), and Western blotting was employed to compare the levels of CREB and phosphorylated CREB (p-CREB). Our results show that p-CREB levels are significantly elevated under 1% oxygen, whereas the total CREB concentration remains unchanged. We further tested whether this phosphorylation is applicable as a marker of hypoxia in pituitary adenoma tissues removed by transsphenoidal surgery from 45 patients (32 females and 13 males, 22-78 years old). Fluorescence double immunohistochemistry data revealed that p-CREB in adenoma tissues is significantly elevated, and displays a positive correlation with Knosp grading (Spearman rank correlation; P = 0.0483, r = 0.3412), but no significant association with tumor subtype (Kruskal-Wallis analysis, CREB, P = 0.1072; p-CREB, P = 0.1888; phosphorylation ratio, P = 0.4916). Our findings collectively suggest that CREB phosphorylation may be employed as an in situ marker for hypoxia. Moreover, hypoxia and/or phosphorylation of CREB are associated with the cell invasiveness of pituitary adenomas.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16598418     DOI: 10.1007/s11060-006-9131-3

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  40 in total

1.  Computer-assisted neurosurgical navigational system for transsphenoidal surgery--technical note.

Authors:  M Onizuka; Y Tokunaga; A Shibayama; H Miyazaki
Journal:  Neurol Med Chir (Tokyo)       Date:  2001-11       Impact factor: 1.742

2.  Erythropoietin receptor is not a surrogate marker for tumor hypoxia and does not correlate with survival in head and neck squamous cell carcinomas.

Authors:  Ilse J Hoogsteen; Wenny J M Peeters; Henri A M Marres; Paul F J W Rijken; Franciscus J A van den Hoogen; Albert J van der Kogel; Johannes H A M Kaanders
Journal:  Radiother Oncol       Date:  2005-08       Impact factor: 6.280

Review 3.  Hypoxia-inducible factor 1alpha in oral cancer.

Authors:  P A Brennan; N Mackenzie; M Quintero
Journal:  J Oral Pathol Med       Date:  2005-08       Impact factor: 4.253

4.  Hypoxia, angiogenesis and apoptosis markers in locally advanced rectal cancer.

Authors:  George E Theodoropoulos; Andreas C Lazaris; Vasilios E Theodoropoulos; Kalliopi Papatheodosiou; Maria Gazouli; John Bramis; Efstratios Patsouris; Dimitrios Panoussopoulos
Journal:  Int J Colorectal Dis       Date:  2005-07-29       Impact factor: 2.571

5.  Regulation of phosphoglucose isomerase/autocrine motility factor expression by hypoxia.

Authors:  Tatsuyoshi Funasaka; Takashi Yanagawa; Victor Hogan; Avraham Raz
Journal:  FASEB J       Date:  2005-09       Impact factor: 5.191

6.  Human HIF-3alpha4 is a dominant-negative regulator of HIF-1 and is down-regulated in renal cell carcinoma.

Authors:  Mindy A Maynard; Andrew J Evans; Tomoko Hosomi; Shuntaro Hara; Michael A S Jewett; Michael Ohh
Journal:  FASEB J       Date:  2005-09       Impact factor: 5.191

7.  Expression of cyclic adenosine 3',5'-monophosphate (cAMP)-responsive element binding protein and inducible-cAMP early repressor genes in growth hormone-secreting pituitary adenomas with or without mutations of the Gsalpha gene.

Authors:  A Peri; B Conforti; S Baglioni-Peri; P Luciani; F Cioppi; L Buci; S Corbetta; E Ballaré; M Serio; A Spada
Journal:  J Clin Endocrinol Metab       Date:  2001-05       Impact factor: 5.958

8.  Phosphorylation-dependent targeting of cAMP response element binding protein to the ubiquitin/proteasome pathway in hypoxia.

Authors:  C T Taylor; G T Furuta; K Synnestvedt; S P Colgan
Journal:  Proc Natl Acad Sci U S A       Date:  2000-10-24       Impact factor: 11.205

9.  Clinical significance of Ki-67 labeling index in pituitary macroadenoma.

Authors:  Kyung-Il Paek; Seon-Hwan Kim; Shi-Hun Song; Seung-Won Choi; Hyeon-Song Koh; Jin-Young Youm; Youn Kim
Journal:  J Korean Med Sci       Date:  2005-06       Impact factor: 2.153

10.  Expression of serine proteases and metalloproteinases in human pituitary adenomas and anterior pituitary lobe tissue.

Authors:  Ulrich J Knappe; Christian Hagel; Björn W Lisboa; Waldemar Wilczak; Dieter K Lüdecke; Wolfgang Saeger
Journal:  Acta Neuropathol       Date:  2003-08-02       Impact factor: 17.088

View more
  1 in total

1.  Upregulation of adenylate cyclase 3 (ADCY3) increases the tumorigenic potential of cells by activating the CREB pathway.

Authors:  Seung-Hyun Hong; Sung-Ho Goh; Sang Jin Lee; Jung-Ah Hwang; Jieun Lee; Il-Ju Choi; Hyehyun Seo; Jong-Hoon Park; Hiromu Suzuki; Eiichiro Yamamoto; In-Hoo Kim; Jin Sook Jeong; Mi Ha Ju; Dong-Hee Lee; Yeon-Su Lee
Journal:  Oncotarget       Date:  2013-10
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.